The Cardiopulmonary Function Outcome and the Effect of Two Modules of Home-based Rehabilitation Programs in Patients After COVID-19 Infection - A Randomized and Controlled Trial.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- National Taiwan University Hospital
- Enrollment
- 13
- Locations
- 1
- Primary Endpoint
- Change of 6-minute walking test (6MWT) and exercise capacity
- Status
- Terminated
- Last Updated
- last year
Overview
Brief Summary
To follow up the cardiopulmonary function after coronavirus disease 2019 (CoVID-19) infection and compare the effect of a 12-week home-based cardiopulmonary with or without add-on remote rehabilitation on the cardiopulmonary function, emotion and quality of outcome.
Detailed Description
The investigators will recruit the patients post-CoVID infection for a cardiopulmonary function evaluation and a home-based rehabilitation program. The investigators hypothesize that an add-on remote rehabilitation on a home-based rehabilitation has a better effect than a home-based rehabilitation alone on the compliance rate for the exercise, and also a better outcome in terms of cardiopulmonary function testing, 6-minute walking test, physical activities and quality of life, as well as less dyspnea, depression and anxiety.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Change of 6-minute walking test (6MWT) and exercise capacity
Time Frame: The change in 6MWT and peak oxygen uptake will be measured at baseline, 12 weeks, 6 and 12 months after intervention.
The distance of a 6-minute walking test and peak oxygen uptake according to cardiopulmonary exercise test will be assessed before intervention (12-week rehabilitation course), 12 weeks, 6 months and 12 months after intervention.
Secondary Outcomes
- Fatigue(The change in BFI will be measured at baseline, 12 weeks, 6 and 12 months after intervention.)
- Cognitive evaluation(The change in MoCA will be measured at baseline, 12 weeks, 6 and 12 months after intervention.)
- Dyspnea scale(The change in mMRC will be measured at baseline, 12 weeks, 6 and 12 months after intervention.)
- Depression and anxiety(The change in PHQ-9 and GAD-7 will be measured at baseline, 12 weeks, 6 and 12 months after intervention.)
- Quality of life evaluation(The change in EQ-5D will be measured at baseline, 12 weeks, 6 and 12 months after intervention.)
- Grip strength(The change in grip strength will be measured at baseline, 12 weeks, 6 and 12 months after intervention.)